When Should You Stop Wegovy — and What Does the Evidence Say?

What the six-month check actually measures

The NICE TA875 recommendation is precise: if a patient has not lost at least 5% of their initial body weight after six months at the maintenance dose of 2.4 mg, the guidance says treatment should stop. The logic is straightforward, the medicine is not producing meaningful benefit, so continued use cannot be justified clinically or economically.

It matters that this threshold is measured at the maintenance dose, not at the lower starter doses used during titration. Early weeks on semaglutide are spent on 0.25 mg and 0.5 mg, doses designed to settle the digestive system, not drive weight loss, and understanding when to take Wegovy correctly throughout that titration schedule makes a real difference to how well the treatment beds in. The six-month clock starts from the clinical picture at 2.4 mg. If you want to read more about the evidence underpinning the full treatment course, the Wegovy overview page covers the STEP trial programme in detail.

Outside the NHS pathway, a private prescriber applies similar clinical reasoning. If the medicine is not working for you biologically, your prescriber should be raising that conversation. The STEP 1 trial, published in the New England Journal of Medicine, recorded around 15% average weight reduction over 68 weeks in adults who did respond, but response is not universal, and the clinical stopping criteria exist precisely for that reason.

When stopping is clinically urgent rather than planned

Some situations require stopping sooner, and waiting for a scheduled review is not appropriate. These include suspected acute pancreatitis (severe stomach pain that radiates to the back, with or without vomiting, that does not ease) or a serious allergic reaction. The MHRA issued a Drug Safety Update in January 2026 specifically highlighting pancreatitis as an infrequent but serious risk with GLP-1 medicines; urgent medical attention is needed, not a wait-and-see approach.

Pregnancy, trying to conceive, and breastfeeding are absolute reasons to stop. Semaglutide is not recommended in any of these situations. If you become pregnant while on Wegovy, the medicine should be discontinued and your GP informed promptly. The same applies if a new medical condition develops that your prescriber was not aware of when they approved your treatment. Questions about any of these situations are best put directly to your clinical team, our support line is available seven days a week if you need to reach us.

For people reaching the two-year NHS maximum under TA875, the end of funded treatment should be a planned conversation, not a surprise. Your specialist team should discuss what ongoing lifestyle support looks like and whether any continuation route applies to your situation.

What happens to weight when Wegovy stops

The STEP 1 trial extension data (and subsequent real-world evidence) consistently shows that weight regain begins after semaglutide is discontinued. On average, participants regained a substantial proportion of the weight they had lost within a year of stopping, without changes to diet or activity. This does not mean treatment has failed. Obesity is a chronic condition, and the biology that drives it does not disappear when a medicine is withdrawn.

That reality shapes how stopping should be planned. A gradual, supported exit (with a nutrition and activity plan in place) tends to produce better long-term outcomes than stopping mid-week because the pen ran out or a delivery was delayed. If timing matters to you practically (payday, a Monday order to avoid a mid-week disruption, a holiday), factor that into the conversation with your prescriber ahead of time rather than after. There is more on managing the practicalities of stopping Wegovy if you are thinking this through now.

For those considering whether Wegovy is still right for them rather than stopping altogether, understanding the specific weight-loss stopping criteria in more depth may help clarify the decision. And if you are wondering whether a different treatment might suit you better, a fresh clinical assessment is the right starting point, you can start a free consultation with our GPhC-registered prescribers to explore your options.

Private treatment and stopping decisions

On a private prescription, there is no mandatory two-year cut-off, but there is the same clinical obligation to review whether the medicine continues to benefit you. At nume, every repeat order is clinically re-reviewed before dispatch. That means a prescriber looks at your progress each time, not just at the start. If the evidence no longer supports continuing, that is a conversation our team will have with you directly.

Stopping a treatment you have been on for months is not a failure. It is a clinical decision like any other. If you are weighing up when to stop using Wegovy specifically or whether now is the right moment for your situation, the clearest answer comes from a prescriber who knows your history. Our clinical team reviews consultations the same day, and any ongoing patient can reach us through the FAQs or direct support if they need guidance between scheduled reviews.